A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
A phase 1/2 trial of Cemiplimab in metastatic cancer and melanoma, run by OncoResponse, Inc., now recruiting.
Overview
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents is a phase 1/2 interventional study registered as NCT06090266 by OncoResponse, Inc., with 168 participants planned, started 2023-10-24 and due to reach its primary completion in 2026-08-01. Interventions recorded: OR502, Cemiplimab. Conditions listed: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Shares Cemiplimab, Metastatic cancer (cancer that has spread).
- TrialA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialNeoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav
Shares Cemiplimab, Melanoma.